We are excited to announce the first implementation of our GMP-compliant Flowfect Tx™ cellular engineering platform. GMP Manufacturing of non-viral engineered cells at clinical and commercial levels has now been validated externally by our commercial partner. "We are committed to leading the way in helping the industry accelerate development and address the challenges in the manufacture of advanced cell therapies. This is the first of many applications in our pipeline and we are eager to partner with therapeutic companies worldwide.” – CEO, Dr. Michael Chiu Read the full press release: https://lnkd.in/gac4E3EB #celltherapy #regenerativemedicine #cancer #cancerresearch #geneediting
Kytopen
Biotechnology Research
Cambridge, Massachusetts 3,980 followers
Open cells to new possibilities: Accelerating cell therapy processes from discovery through manufacturing with Flowfect®
About us
Kytopen is focused on the development and commercialization of groundbreaking genome engineering platforms for expediting the discovery, development, and manufacture of gene-modified cell therapies. Developed at MIT, the Flowfect® platform, harmonizing microfluidics and automation, revolutionizes the delivery of genome engineering materials to cells of therapeutic interest in an expeditious, scalable, and economically advantageous manner compared to current alternatives. In May 2023, Kytopen unveiled the Flowfect Discover™, an automated high-throughput genome engineering platform, and disclosed strategic partnerships with industry-leading Contract Development and Manufacturing Organizations (CDMOs) and translational academic medical centers. By combining Flowfect Discover™ with the Flowfect Tx™ large-scale delivery device in process development workflows, developers can now surmount manufacturing challenges during the discovery stage, fostering swifter and more cost-effective innovation.
- Website
-
https://kytopen.com/
External link for Kytopen
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
- Founded
- 2017
- Specialties
- Transfection, Immunotherapy, Cell engineering, Mechanical engineering, Genetic engineering, Mammalian cells, Manufacturing, Immunology, CRISPR, CAR T-cell, Drug Discovery, Cell Therapy, Gene Therapy, Stem Cells, Gene Editing, mRNA, RNP delivery, NK cells, CD34+ stem cells, T cells, Cas9, and Nonviral
Locations
-
Primary
Get directions
750 Main St
Cambridge, Massachusetts 02139, US
Employees at Kytopen
-
Vinit Nijhawan (he/him)
Investor, Entrepreneur, Academic
-
Mikhail Shapiro
Professor at Caltech, Investigator at HHMI, Founder and Adviser
-
David D. Barone
VP of Product Development and Operations at Kytopen
-
Brad Hamilton
Scientific Executive | Biotech Founder | Cell & Gene Therapy (Technology Application/Development/Strategy)
Updates
-
Kytopen is excited to announce Kevin Gutshall as our new Chief Commercial Officer. Kevin says, "Kytopen is poised to deliver a platform that dramatically transforms the scale and yield that current advanced therapeutic medicine developers are achieving." Welcome to the team, Kevin! Read the full press release here: https://hubs.la/Q02s5Ss_0
-
-
Kytopen reposted this
March was an exciting month for the next-generation therapeutics field. In the Cell Therapy space, NKGen Biotech, Inc. announced positive data for their autologous NK cell therapy, while a CAR-T cell product produced dramatic responses in patients with glioblastoma in a preliminary clinical trial at Mass General Cancer Center. Kytopen also announced their technology access program for their Flowfect platform, while Fiocruz and Caring Cross teamed up to manufacture CAR-T cells at a lower cost. In the ADC space, new partnerships were announced this past month, including Biocytogen’s collaboration with ABL Bio Inc. to develop bispecific ADCs and Biotheus Inc. expanding their collaboration with Jiangsu Hansoh Pharmaceutical Group Co., Ltd.. BrickBio, Inc. also announced compelling preclinical data showing complete tumor eradication in animal models treated with Pyrrolobenzodiazepine, while Bio-Thera Solutions received IND clearance for a Phase II study with BAT8006. In the Gene Therapy space, Nanoscope Therapeutics Inc. announced positive data for MCO-010 in vision loss, while Sangamo Therapeutics, Inc. announced exciting data with their AAV capsid variant STAC-BBB and Tenaya Therapeutics reported positive preclinical data for TN-401 in a rare heart condition. Charles River Laboratories and Navega Therapeutics also announced their partnership to expand manufacturing capabilities for the AAV gene therapy candidate NT-Z001. In the Oligo Therapy space, Silence Therapeutics plc announced positive data from a Phase 2 study with Zerlasiran in patients with high lipoprotein(a), while Moderna’s next-generation COVID vaccine achieved a higher immune response in a Phase 3 clinical trial. Capstan Therapeutics announced that they secured $175 million in a Series B financing round, while Blackstone announced their collaboration with Moderna, in which they will provide up to $750 million for mRNA-based influenza vaccines. Read on to see additional developments that occurred in March here: https://lnkd.in/gkxeDHNq Subscribe to our newsletter on Linkedin: https://lnkd.in/gMfy6_YZ Sign up to receive our Next-Generation Therapeutics Newsletter in your email: https://lnkd.in/gKQn7_zp These headlines were curated by Rebecca Burnham, PhD, Joe Daccache, Ph.D., Luka Jelcic, Juilee Malavade, Ph.D., and Carl Schoellhammer. #precisionmedicine #nextgenerationtherapeutics #celltherapy #genetherapy #oligotherapy #antibodydrugconjugates #decibio #innovation #biotechnology
-
Attending the Alliance for Regenerative Medicine #MeetingOnTheMed? Make sure to say hello to Luke Ursell and Kevin Gutshall this week while you're there. Talk to them about our recently launched Technology Access Program and learn more about how Flowfect® can fit your needs.
-
-
Kytopen reposted this
Who's attending our 2024 Cell & Gene Meeting on the Med on April 9-11? We're expecting 600+ attendees from 250+ leading cell and gene therapy companies. See the complete list of companies attending and begin setting up your partnering meetings today: https://lnkd.in/gPTUsBBj #cellandgenetherapy #CGMed24
Attendees
https://meetingonthemed.com
-
Did you hear the news? Kytopen is launching our Technology Access Program, helping our partners optimize their workflows using our non-viral Flowfect® platform! Visit https://lnkd.in/eSC3JNtK to learn more, and read the full press release here: https://hubs.la/Q02qKYzV0
-
-
Happy #InternationalWomensDay from all of us at Kytopen to you 🩷 How will you celebrate the women in your life today?
-
-
Check out our CEO on “Conversations Life Sciences Leaders Aren’t Having”!
Most of the pre-commercial resources in drug development are put towards the science. And rightfully so. However, Michael Chiu from Kytopen invites life science leaders to consider manufacturing and how we'll deliver to the patient earlier in the process. Listen to our full podcast conversation in one of the links in the first comment. #ceo #lifescience #servantleadership
-
Check it out! Michael Chiu shares his experience in the latest episode of Conversations Life Science Leaders Aren't Having.
Tune in to this week’s episode of Conversations Life Science Leaders Aren't Having. We welcomed Michael Chiu, CEO of Kytopen, Inc. Michael doesn't describe himself as a visionary CEO but as an operations-focused leader. He's focused on defining the problem and aligning his team around a shared definition of success. This isn't glamorous. It's about the relentless grind and bridging the gap between ideas and execution. Michael helps us see a new way to frame "punches in the mouth" as not a failure at all. Rather, they are ways to learn, better meet the client’s needs and be more successful. Listen in and here’s what you’ll learn about: - Frame the problem properly - You need a framework so everyone is aligned - Focus more on delivering the science - Go out there and fail - Reframing failure as not failing Conversations Life Science Leaders Aren't Having is LIVE today on Spotify, Apple Podcasts, and YouTube.
-
-
Attending the 30th Annual European Society of Gene and Cell Therapy Congress in Brussels this week? Learn about how the Kytopen team has optimized transfection with #Flowfect® for natural killer cells and RNP! Stop by the poster sessions to see Gretchen Lewis Wednesday and Thursday evenings and learn more. #cellandgenetherapy #celltherapymanufacturing #esgct #nonviral
-